Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Protein kinase Cα-mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes it.

Tedja R, Roberts CM, Alvero AB, Cardenas C, Yang-Hartwich Y, Spadinger S, Pitruzzello M, Yin G, Glackin CA, Mor G.

J Biol Chem. 2019 Mar 29;294(13):5082-5093. doi: 10.1074/jbc.RA118.005921. Epub 2019 Feb 7.

PMID:
30733340
2.

p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT.

Yang-Hartwich Y, Tedja R, Roberts CM, Goodner-Bingham J, Cardenas C, Gurea M, Sumi NJ, Alvero AB, Glackin CA, Mor G.

Mol Cancer Res. 2019 Jan;17(1):153-164. doi: 10.1158/1541-7786.MCR-18-0238. Epub 2018 Aug 21.

PMID:
30131448
3.

The unique immunological and microbial aspects of pregnancy.

Mor G, Aldo P, Alvero AB.

Nat Rev Immunol. 2017 Aug;17(8):469-482. doi: 10.1038/nri.2017.64. Epub 2017 Jun 19.

PMID:
28627518
4.

Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model.

Alvero AB, Kim D, Lima E, Sumi NJ, Lee JS, Cardenas C, Pitruzzello M, Silasi DA, Buza N, Fahmy T, Mor G.

Sci Rep. 2017 Jan 25;7:40989. doi: 10.1038/srep40989.

5.

Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells.

Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G, Alvero AB.

Apoptosis. 2017 Apr;22(4):558-569. doi: 10.1007/s10495-016-1339-x.

PMID:
28012060
6.

Redefining the origin and evolution of ovarian cancer: a hormonal connection.

Cardenas C, Alvero AB, Yun BS, Mor G.

Endocr Relat Cancer. 2016 Sep;23(9):R411-22. doi: 10.1530/ERC-16-0209. Epub 2016 Jul 20. Review.

PMID:
27440787
7.

TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.

Alvero AB, Heaton A, Lima E, Pitruzzello M, Sumi N, Yang-Hartwich Y, Cardenas C, Steinmacher S, Silasi DA, Brown D, Mor G.

Mol Cancer Ther. 2016 Jun;15(6):1279-90. doi: 10.1158/1535-7163.MCT-16-0005. Epub 2016 Apr 8.

8.

Detection of p53 protein transcriptional activity by chromatin immunoprecipitation.

Yang-Hartwich Y, Romanoff E, Bingham J, Alvero AB, Mor G.

Methods Mol Biol. 2015;1219:87-93. doi: 10.1007/978-1-4939-1661-0_8.

PMID:
25308264
9.

Detection of p53 protein aggregation in cancer cell lines and tumor samples.

Yang-Hartwich Y, Bingham J, Garofalo F, Alvero AB, Mor G.

Methods Mol Biol. 2015;1219:75-86. doi: 10.1007/978-1-4939-1661-0_7.

PMID:
25308263
10.
11.

Ovulation and extra-ovarian origin of ovarian cancer.

Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB, Mor G.

Sci Rep. 2014 Aug 19;4:6116. doi: 10.1038/srep06116.

12.

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.

Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, Alvero AB, Mor G.

Cancer Med. 2013 Dec;2(6):751-62. doi: 10.1002/cam4.115. Epub 2013 Aug 27. Erratum in: Cancer Med. 2013 Dec;2(6):987. Joo, Won Duk [added].

13.

TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.

Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P, Mor G.

Cell Cycle. 2013 Feb 1;12(3):511-21. doi: 10.4161/cc.23406. Epub 2013 Jan 16.

14.

Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential.

Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T, Mor G.

Oncogene. 2013 Jan 3;32(1):39-49. doi: 10.1038/onc.2012.33. Epub 2012 Feb 20.

15.

Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype.

Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G.

Am J Reprod Immunol. 2012 Mar;67(3):256-65. doi: 10.1111/j.1600-0897.2011.01068.x. Epub 2011 Sep 14.

16.

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.

Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G.

J Oncol. 2011;2011:620523. doi: 10.1155/2011/620523. Epub 2011 Aug 29.

17.

Modulation and recruitment of inducible regulatory T cells by first trimester trophoblast cells.

Ramhorst R, Fraccaroli L, Aldo P, Alvero AB, Cardenas I, Leirós CP, Mor G.

Am J Reprod Immunol. 2012 Jan;67(1):17-27. doi: 10.1111/j.1600-0897.2011.01056.x. Epub 2011 Aug 7.

18.

Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells.

Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G.

Mol Cancer Ther. 2011 Aug;10(8):1385-93. doi: 10.1158/1535-7163.MCT-11-0023. Epub 2011 Jun 15.

19.

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.

Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler EM.

Anticancer Drugs. 2011 Sep;22(8):719-31. doi: 10.1097/CAD.0b013e328346f3b4.

PMID:
21666438
20.

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.

Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G.

Cell Cycle. 2011 Jul 1;10(13):2206-14. Epub 2011 Jul 1.

21.

Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.

Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, Mor G.

Am J Reprod Immunol. 2011 Jun;65(6):597-609. doi: 10.1111/j.1600-0897.2010.00968.x. Epub 2011 Jan 18.

22.

Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells.

Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T, Mor G.

Am J Reprod Immunol. 2011 Apr;65(4):438-47. doi: 10.1111/j.1600-0897.2010.00914.x. Epub 2010 Sep 6.

23.

Recent insights into the role of NF-kappaB in ovarian carcinogenesis.

Alvero AB.

Genome Med. 2010 Aug 25;2(8):56. doi: 10.1186/gm177.

24.

TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214.

Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G.

Oncogene. 2010 Jun 17;29(24):3545-53. doi: 10.1038/onc.2010.111. Epub 2010 Apr 19.

25.

The isolation and characterization of a novel telomerase immortalized first trimester trophoblast cell line, Swan 71.

Straszewski-Chavez SL, Abrahams VM, Alvero AB, Aldo PB, Ma Y, Guller S, Romero R, Mor G.

Placenta. 2009 Nov;30(11):939-48. doi: 10.1016/j.placenta.2009.08.007. Epub 2009 Sep 18.

26.
27.

Stem-like ovarian cancer cells can serve as tumor vascular progenitors.

Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, Oidtman J, Silasi DA, Mor G.

Stem Cells. 2009 Oct;27(10):2405-13. doi: 10.1002/stem.191.

28.

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB.

J Transl Med. 2009 Jul 20;7:63. doi: 10.1186/1479-5876-7-63.

29.

NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway.

Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, Fu HH, Brown D, Mor G.

Cancer. 2009 Jul 15;115(14):3204-16. doi: 10.1002/cncr.24397.

30.

Development and validation of a protein-based signature for the detection of ovarian cancer.

Kim K, Visintin I, Alvero AB, Mor G.

Clin Lab Med. 2009 Mar;29(1):47-55. doi: 10.1016/j.cll.2009.02.001. Review.

31.

Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs.

Silasi DA, Alvero AB, Rutherford TJ, Brown D, Mor G.

Expert Opin Pharmacother. 2009 Apr;10(6):1059-67. doi: 10.1517/14656560902837980 . Review. Erratum in: Expert Opin Pharmacother. 2009 Jun;10(8):1387.

PMID:
19364253
32.

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.

Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G.

Cell Cycle. 2009 Jan 1;8(1):158-66.

33.

Anti-tumor activity of phenoxodiol: from bench to clinic.

Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, Mor G.

Future Oncol. 2008 Aug;4(4):475-82. doi: 10.2217/14796694.4.4.475. Review.

PMID:
18684059
34.

Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells.

Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G.

Oncogene. 2008 Aug 7;27(34):4712-23. doi: 10.1038/onc.2008.112. Epub 2008 Apr 14.

35.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

36.

Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells.

Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G.

Oncogene. 2008 Jan 7;27(2):225-33. doi: 10.1038/sj.onc.1210907. Review.

PMID:
18176604
37.

Correlation of caspase activity and in vitro chemo-response in epithelial ovarian cancer cell lines.

Alvero AB, Montagna MK, Mor G.

Methods Mol Biol. 2008;414:79-82.

PMID:
18175813
38.

Detection of cancer-related proteins in fresh-frozen ovarian cancer samples using laser capture microdissection.

Silasi DA, Alvero AB, Mor J, Chen R, Fu HH, Montagna MK, Mor G.

Methods Mol Biol. 2008;414:35-45. Review.

PMID:
18175810
39.

Modulation of apoptosis to reverse chemoresistance.

Mor G, Montagna MK, Alvero AB.

Methods Mol Biol. 2008;414:1-12. Review.

PMID:
18175807
40.

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.

Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G.

Yale J Biol Med. 2006 Dec;79(3-4):153-63.

41.

Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects.

Alvero AB, Brown D, Montagna M, Matthews M, Mor G.

Cancer Biol Ther. 2007 Apr;6(4):612-7.

PMID:
17457041
42.

Macrophage migration inhibitory factor expression in ovarian cancer.

Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, Segal EA, Schwartz P, Ward D, Rutherford T, Mor G.

Am J Obstet Gynecol. 2007 Apr;196(4):348.e1-5.

PMID:
17403417
43.
44.

Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway.

Chen R, Alvero AB, Silasi DA, Mor G.

Am J Reprod Immunol. 2007 Feb;57(2):93-107. Review.

PMID:
17217363
45.

Phenoxodiol, a novel approach for the treatment of ovarian cancer.

Mor G, Fu HH, Alvero AB.

Curr Opin Investig Drugs. 2006 Jun;7(6):542-8. Review.

PMID:
16784025
46.

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.

Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G.

Cancer Res. 2006 Apr 1;66(7):3859-68.

47.

Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells.

Alvero AB, Chen W, Sartorelli AC, Schwartz P, Rutherford T, Mor G.

J Soc Gynecol Investig. 2006 Feb;13(2):145-52.

PMID:
16443509
48.

Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.

Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T, Mor G.

Cancer. 2006 Feb 1;106(3):599-608.

49.

Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.

Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, Rutherford T, Mor G.

Oncol Res. 2004;14(11-12):567-78.

PMID:
15666998
50.

Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype.

Alvero AB, Fishman DA, Qumsiyeh MB, Garg M, Kacinski BM, Sapi E.

J Soc Gynecol Investig. 2004 Dec;11(8):553-61.

PMID:
15582501

Supplemental Content

Loading ...
Support Center